Overview

Epinephrine Inhalation Aerosol USP, CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS

Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
This study examines the pharmacokinetic profile of Armstrong's proposed Epinephrine Inhalation Aerosol USP, an HFA134a propelled Metered Dose Inhaler (MDI) (E004), using a stable isotope deuterium-labeled epinephrine (epinephrine-d3) to differentiate the administered drug from the endogenous epinephrine, in healthy male and female adult volunteers.
Phase:
Phase 2
Details
Lead Sponsor:
Amphastar Pharmaceuticals, Inc.
Treatments:
Epinephrine
Epinephryl borate
Racepinephrine